Kawasaki Disease Market

Market Overview:

The 7 major Kawasaki disease markets are expected to exhibit a CAGR of 5.33% during 2024-2034.

The Kawasaki disease market has been comprehensively analyzed in IMARC's new report titled "Kawasaki Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kawasaki disease refers to a rare but potentially serious childhood illness characterized by swelling of blood vessels throughout the body. This disorder primarily affects children under the age of five. The condition presents a constellation of symptoms, including a high fever persisting for at least five days, redness and swelling of the hands and feet, conjunctivitis (red eyes), a rash, and swollen lymph nodes in the neck. Additionally, children suffering from the ailment may experience irritability, a sore throat, and peeling of the skin on the fingers and toes. The diagnosis of Kawasaki disease involves a thorough evaluation of clinical symptoms and medical history, as there are no certain laboratory tests that can definitively confirm the disease. Physicians often rely on a set of diagnostic criteria that take into account the duration and nature of the fever as well as the presence of various other associated indications. Blood workups are commonly used to assess the inflammation causing the underlying condition.

The increasing incidences of abnormal immune responses triggered by an infectious agent or several other environmental factors like temperature, humidity, or changes in viral activity are primarily driving the Kawasaki disease market. In addition to this, the inflating utilization of effective therapeutic interventions, such as intravenous immunoglobulin (IVIG), aspirin, corticosteroids, etc., for the management of illness and mitigation of potential complications is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive treatments, encompassing fever-reducing measures and fluid replacement, owing to their role in alleviating symptoms and bolstering the overall recovery process in patients, is further propelling the market growth. Apart from this, the rising usage of echocardiography as a pivotal diagnostic tool to assess coronary artery involvement and cardiac function is acting as another significant growth-inducing factor. Additionally, the emerging popularity of plasmapheresis in severe cases, aimed at removing harmful antibodies from the bloodstream and reducing organ damage in individuals suffering from the ailment, is also augmenting the market growth. Furthermore, the escalating application of advanced therapeutic avenues, such as monoclonal antibodies and immunomodulatory agents, since they address the underlying immune dysregulation associated with the illness, is expected to drive the Kawasaki disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Kawasaki disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Kawasaki disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Kawasaki disease market in any manner.

Time Period of the Study

•  Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Kawasaki disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Kawasaki disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Kawasaki disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Kawasaki disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Kawasaki disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Kawasaki disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Kawasaki disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Kawasaki disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Kawasaki disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Kawasaki disease across the seven major markets?
• What is the size of the Kawasaki disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Kawasaki disease?
• What will be the growth rate of patients across the seven major markets?
   

Kawasaki Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Kawasaki disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Kawasaki disease market?
• What are the key regulatory events related to the Kawasaki disease market?
• What is the structure of clinical trial landscape by status related to the Kawasaki disease market?
• What is the structure of clinical trial landscape by phase related to the Kawasaki disease market?
• What is the structure of clinical trial landscape by route of administration related to the Kawasaki disease market?